Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily brimonidine tartrate 0.35% vs three-times-daily brimonidine tartrate 0.1% in glaucoma and ocular hypertension
2015-005540-34Phase 2Completed
- Sponsor
- Sun Pharma Advanced Research Company
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of brimonidine in open-angle glaucoma (OAG), chronic angle-closure glaucoma (CACG), pseudoexfoliation syndrome (PXF) and 2 more (2 arms), sponsored by Sun Pharma Advanced Research Company. Primary endpoint: Mean intraocular pressure at Day 84. Started Jun 2016; status: completed.
02
Drugs
brimonidine
03
Conditions
open-angle glaucoma (OAG)chronic angle-closure glaucoma (CACG)pseudoexfoliation syndrome (PXF)pigment dispersion syndrome (PDS)ocular hypertension
Beyond the preview
Go deeper on 2015-005540-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005540-34.